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ABSTRACT 
Some 1-((4-methylpiperazin-1yl)methyl)-1H-benzo[d]imidazole & 1-((4-phenylpiperazin-1yl)methyl)-1H-benzo[d]imidazole derivatives were 
synthesized through reaction of 1-substituted piperazines with different benzimidazole derivatives in methanol yielded the corresponding 
mannich bases (42-a to 42-i). All the synthesized compounds were elucidated by IR, 1H NMR and MASS spectroscopy. They were tested for anti-
inflammatory activity using in-vivo (Carrageenan- induced rat paw edema model) method at a dose of 50mg/kg. result showed that compounds 
42-c, 42-d and 42-h were found to be most potent in series. 
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INTRODUCTION 
Prostaglandins, prostacyclin (PGI2) and thromboxaneA2 
(TXA2) are produced from arachidonic acid by the enzyme 
cyclooxegenase which exists in a constitutive (COX-1) and an 
inducible (COX-2) isoforms. NSAIDs acts by blocking PG 
generation. The classical COX inhibitors are not selective and 
the main adverse effects of their use are peptic ulceration, 
nephrotoxicity and dyspepsia.1 In designing new drug 
molecules, developing safer anti-inflammatory drugs 
without such side effects has recently been the goal of many 
researchers. Piperazine derivatives have been used over the 
past few decades because of the wide range of activities like 
antimicrobials, anthelmintics, antihistamines, anti-HIV, 
hypotensive, anaesthetics, analgesics, anticonvulsants.2-15 
MATERIAL AND METHODS  
Synthetic Route 
Schematic representation of novel piperazine derivatives is 
given following figure;
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SCHEME-1  
Figure 1: Schematic representation of novel piperazine derivatives 
 
Synthetic Procedure 
Synthetic Procedure for Preparation of Benzimidazole 
Derivatives (41a-e) 
Synthesis of benzimidazole (41-a)16 
0.025mol of o-phenylenediamine was placed in a 250ml RBF 
and 0.034mol of 90% formic acid was added. The mixture 
was heated on water bath for 2hrs. Cooled, 10% NaOH 
solution was added slowly with constant rotation of flask 
until the mixture is just alkaline to litmus. The crude 
benzimidazole was filtered off at the pump, washed with ice-
cold water, drained well and washed again with 5ml of cold 
water. The crude product was dissolved in 40ml of boiling 
water, 0.2g of decolorizing carbon and digested for 15min. 
The product was filtered of rapidly at the pump through a 
preheated Buchner funnel and flask. The filtrate was cooled 
to about 10°C, benzimidazole was filtered off, washed with 
5ml of cold water and dried at 100°C. 
Synthesis of 2-methyl benzimidazole (41-b) & 2-benzyl 
benzimidazole (41-e)16 
A mixture of 0.03mol of o-phenylenediamine 
dihydrochloride, 20ml of water 0.09mol of acetic 
acid/phenylacetic acid was refluxed for 2hrs.The reaction 
mixture was cooled and made it distinctly basic by gradual 
addition of concentrated ammonia solution, the precipitated 
product was collected and recrystallized it from 10% 
aqueous methanol. 
Synthesis of 2-ethyl benzimidazole (41-c) 14 
A mixture of 0.03mol of o-phenylenediamine 
dihydrochloride, 20ml of water and 0.09mol of propionic 
acid was refluxed for 2hrs.The reaction mixture was cooled 
and made it distinctly basic by gradual addition of 
concentrated ammonia solution, the precipitated product 
was collected and recrystallized it from 10% aqueous 
methanol. 
Synthesis of 2-phenyl benzimidazole (41-d) 17 
0.01mol o-phenylenediamine and 0.01mol of benzaldehyde 
were mixed in 10ml DMF,  0.003mol of sodium bisulphate 
was added and the mixture was stirred at 80°C for 6hr. The 
mixture was cooled to room temperature and added 
dropwise to cold water under vigorous stirring. The product 
separated as gummy material was extracted with 
ethylacetate. The extract was washed with water, brine 
solution, dried over sodium sulphate and evaporated. The 
residue thus obtained was recrystallized from ethanol to 
afford compound. 
General procedure for the synthesis of Mannich bases 
(42-a-j)14,18 
0.01mol of benzimidazole derivatives (41a-e) in 20ml of 
methanol was stirred at room temperature with 0.01mol of 
1-methyl piperazine/1-phenyl piperazine, l ml formaldehyde 
solution (40%w/v) and 1ml concentrated HCl. Then the 
reaction mixture was refluxed for 10hrs at 70-75°C. The hot 
mixture was filtered and kept in refrigerator overnight. The 
product precipitated out and was filtered, dried and 
recrystallized from ethanol to give solid compound. 
Biological Evaluation19 
Albino wistar rats of either sex (150-200 g) were divided 
into six groups of three animals each. Animals were deprived 
of food for 12 hours prior to the experiment and only water 
was given. First group was used as a control and received 1 
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ml of 1 % w/v PVP suspension in saline, the second group 
received PVP suspension of Aspirin (50 mg/kg) orally and 
the remaining four groups received PVP suspension of test 
compounds at a dose of 50 mg/kg orally. One hour after the 
administration of the compounds, carrageenan suspension 
(0.1 ml of 1% w/v suspension in 0.9% saline solution) was 
injected into the sub planter region of right hind paw of the 
animals. Immediately, the paw thickness was measured from 
the ventral to the dorsal surface using a digital vernier 
caliper (initial paw thickness, Tc). Thereafter, the paw 
thickness was measured after 1 and 3hrs after carrageenan 
administration. Data was shown as increase in paw 
thickness and % inhibition of paw edema produced by 
treated groups. 
% inhibition of paw edema by using given formula:  
% Inhibition = [1- (Tt/Tc)] × 100 
RESULTS 
Synthesis of piperazine derivatives (42-a-j) done as per 
given scheme. The physical data of intermediates (41-a-e) & 
synthesized derivatives (42-a-j) are given in table 1 & table 2 
respectively. Structures of synthesized compounds were 
characterized by NMR, IR, MASS spectroscopy. In the same 
way, the result of the biological evaluation of the prepared 
derivatives is also shown in table 3.  
 
 
 
Physical characteristics of 2-substituted benzimidazole (41a-e) 
N
H
N
R
 
Table 1  Physical characteristics of 2-substituted benzimidazole 
Code no. R 
Molecular 
formula 
Molecular 
weight 
(g/mol) 
Melting point 
(˚C) 
Yield 
(%) 
 
Rf * 
41-a H C7H6N2 118.14 168-170  59.65 0.52 
41-b CH3 C8H8N2 132.16 172-174  54.75 0.56 
41-c C2H5 C9H10N2 146.19 170-172  55.80 0.59 
41-d C6H5 C13H10N2 194.23 286-288  52.68 0.61 
41-e CH2C6H5 C14H12N2 208.26 186-188  55.86 0.65 
    *Solvent system: n-hexane: ethyl acetate (3:2) 
 
Physical characteristics of targeted compounds (42a-j) 
NNR1 CH2
N
N
R
 
Table 2  Physical characteristics of targeted compounds 
Code no. R R1 
Molecular 
formula 
Molecular 
weight (g/mol) 
Melting point 
(˚C) 
Yield 
(%) 
Rf * 
42-a H CH3 C13H18N4 230.31 230-232 47.68 0.60 
42-b CH3 CH3 C14H20N4 244.34 238-240 45.66 0.62 
42-c C2H5 CH3 C15H22N4 258.36 234-236 52.86 0.65 
42-d C6H5 CH3 C19H22N4 306.40 >300 40.52 0.66 
42-e CH2C6H5 CH3 C20H24N4 320.43 240-242 43.25 0.69 
42-f H C6H5 C18H20N4 292.38 236-238 44.15 0.63 
42-g CH3 C6H5 C19H22N4 306.40 242-244 42.50 0.65 
42-h C2H5 C6H5 C20H24N4 320.43 238-240 53.56 0.67 
42-i C6H5 C6H5 C24H24N4 368.47 >300 41.52 0.70 
42-j CH2C6H5 C6H5 C25H26N4 382.50 246-248 51.86 0.72 
        *Solvent system: benzene: methanol (3:2) 
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Spectral characteristics of targeted compounds 
1-((4-methylpiperazin-1yl)methyl)-1H-benzo[d]imidazole 
(42-a) 
(KBr) cm-1: 3058 (aromatic CH stretch), 2967(aliphatic CH 
stretch), 1182 (C-N) 1656(C=N) 1H NMR (δ, ppm): 2.15 (s, 
3H, N-CH3),  2.30  (s, 8H, 4CH2 of piperazine), 4.81 (s, 2H, N-
CH2-N),  7.19-7.27 (m, 2H, Ar-H), 7.62 (d, 2H, Ar-H), 8.18 (s, 
1H, N-CH2=N). EIMS(m/z): 230 (M+). Elemental analysis: 
(found/calculated) C, 67.71/67.80; H, 7.91/7.88; N, 
24.38/24.33 
2-methyl-1-((4-methylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-b)  
(KBr) cm-1: 3098 (aromatic CH stretch), 2971(aliphatic CH 
stretch), 1267 (C-N), 1615(C=N) 1H NMR (δ, ppm): 2.14 (s, 
3H, N-CH3),  2.31 (s, 8H, 4CH2 of piperazine), 2.52 (s, 3H, CH3 
of 2-methyl benzimidazole) 4.80 (s, 2H, N-CH2-N),  7.18-7.27 
(m, 2H, Ar-H), 7.52-7.64 (m, 2H, Ar-H). EIMS(m/z): 244 (M+). 
Elemental analysis: (found/calculated) C, 68.78/68.82; H, 
8.20/8.25; N, 23.02/22.93 
2-ethyl-1-((4-methylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-c)  
(KBr) cm-1: 3053 (aromatic CH stretch), 2920(aliphatic CH 
stretch), 1255 (C-N), 1638(C=N). 1H NMR (δ, ppm): 1.27 (t, 
3H, CH3 of 2-ethyl benzimidazole), 2.13 (s, 3H, N-CH3),  2.33 
(s, 8H, 4CH2 of piperazine), 2.81 (m, 2H, CH2 of 2-ethyl 
benzimidazole), 4.79 (s, 2H, N-CH2-N), 7.17-7.26 (m, 2H, Ar-
H), 7.53-7.64 (m, 2H, Ar-H)    EIMS(m/z): 258 (M+). 
Elemental analysis: (found/calculated) C, 69.69/69.73; H, 
8.60/8.58; N, 21.71/21.69 
1-((4-methylpiperazin-1yl)methyl)- 2-phenyl-1H-
benzo[d]imidazole (42-d) 
(KBr) cm-1: 759 (aromatic CH out-of-plane bend), 
2925(aliphatic CH stretch), 1165 (C-N), 1626(C=N). 1H NMR 
(δ, ppm): 2.13 (s, 3H, N-CH3),  2.32 (s, 8H, 4CH2 of 
piperazine), 4.81 (s, 2H, N-CH2-N),  7.25-7.27 (t, 2H, Ar-H), 
7.49 (t, 3H, Ar-H), 7.64-7.70 (m, 2H, Ar-H), 8.26 (d, 2H, Ar-H). 
EIMS(m/z): 306 (M+). Elemental analysis: 
(found/calculated) C, 74.44/74.48; H, 7.23/7.24; N, 
18.33/18.29 
2-benzyl-1-((4-methylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-e) 
(KBr) cm-1: 3061 (aromatic CH stretch), 2943(aliphatic CH 
stretch), 1235 (C-N), 1648(C=N).  1H NMR (δ, ppm): 2.14 (s, 
3H, N-CH3),  2.30 (s, 8H, 4CH2 of piperazine), 4.00 (s, 2H, CH2 
of 2-benzyl benzimidazole), 4.80 (s, 2H, N-CH2-N), 7.15-7.28 
(m, 9H, Ar-H), 7.51  (d, 1H, Ar-H), 7.65 (d,1H, Ar-H)  
EIMS(m/z): 320 (M+). Elemental analysis: 
(found/calculated) C, 74.92/74.97; H, 7.56/7.55; N, 
17.52/17.48 
1-((4-phenylpiperazin-1yl)methyl)-1H-benzo[d]imidazole 
(42-f)  
(KBr) cm-1: 749 (aromatic CH), 2924(aliphatic CH stretch), 
1122 (C-N), 1612(C=N). 1H NMR (δ, ppm): 2.45 (t, 4H, 2CH2 
of piperazine), 3.45 (t, 4H, 2CH2 of piperazine), 4.81 (s, 2H, N-
CH2-N), 6.80 (t, 1H, Ar-H of phenyl piperazine), 6.93 (d, 2H, 
Ar-H of phenyl piperazine), 7.20-7.27 (m, 4H, Ar-H), 7.61 (d, 
2H, Ar-H), 8.19 (s, 1H, N-CH2=N) EIMS(m/z): 292(M+). 
Elemental analysis: (found/calculated) C, 73.98/73.94; H, 
6.85/6.89; N, 19.17/19.16 
2-methyl-1-((4-phenylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-g)  
(KBr) cm-1: 3053 (aromatic CH stretch), 2974(aliphatic CH 
stretch), 1271(C-N), 1622(C=N) 1H NMR (δ, ppm): 2.43 (t, 
4H, 2CH2 of piperazine), 2.51 (s, 3H, CH3 of 2-methyl 
benzimidazole), 3.45 (t, 4H, 2CH2 of piperazine), 4.82 (s, 2H, 
N-CH2-N), 6.77 ( t, 1H, Ar-H of phenyl piperazine), 6.92 (d, 
2H, Ar-H of phenyl piperazine), 7.20-7.27 (m, 4H, Ar-H), 
7.51-7.63 (d, 2H, Ar-H) EIMS(m/z): 306(M+). Elemental 
analysis: (found/calculated) C, 74.41/74.48; H, 7.25/7.24; N, 
18.34/18.29 
2-ethyl-1-((4-phenylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-h)  
(KBr) cm-1: 3050 (aromatic CH stretch), 2988(aliphatic CHV 
stretch), 1222 (C-N), 1623(C=N) 1H NMR (δ, ppm): 1.28 (t, 
3H, CH3 of 2-ethyl benzimidazole), 2.45 (t, 4H, 2CH2 of 
piperazine), 2.80 (m, 2H, CH2 of 2-ethyl benzimidazole), 3.44 
(t, 4H, 2CH2 of piperazine), 4.80 (s, 2H, N-CH2-N), 6.80 (t, 1H, 
Ar-H), 6.94 (d, 2H, Ar-H), 7.21-7.27 (m, 4H, Ar-H), 7.53 (d, 
1H, Ar-H), 7.64 (d,1H, Ar-H) EIMS(m/z): 320(M+). Elemental 
analysis: (found/calculated) C, 74.88/74.97; H, 7.57/7.55; N, 
17.55/17.48 
2-phenyl- 1-((4-phenylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-i)  
(KBr) cm-1: 3004 (aromatic CH stretch), 2835(aliphatic CH 
stretch), 1268(C-N), 1622(C=N) 1H NMR (δ, ppm): 2.45 (t, 
4H, 2CH2 of piperazine), 3.45 (t, 4H, 2CH2 of piperazine), 4.76 
(s, 2H, N-CH2-N), 6.83 (t, 1H, Ar-H), 6.96 (d, 2H, Ar-H), 7.20-
7.27 (m, 4H, Ar-H), 7.52 (d, 3H, Ar-H), 7.63-7.69 (m, 2H, Ar-
H), 8.29 (d, 2H, Ar-H) EIMS(m/z): 368(M+). Elemental 
analysis: (found/calculated) C, 78.18/78.23; H, 6.59/6.57; N, 
15.23/15.21 
2-benzyl-1-((4-phenylpiperazin-1yl)methyl)-1H-
benzo[d]imidazole (42-j)  
(KBr) cm-1: 3063 (aromatic CH stretch), 2942(aliphatic CH 
stretch), 1286 (C-N), 1668(C=N).  1H NMR (δ, ppm): 2.44 (t, 
4H, 2CH2 of piperazine), 3.42 (t, 4H, 2CH2 of piperazine), 4.00 
(s, 2H, CH2 of 2-benzyl benzimidazole), 4.82 (s, 2H, N-CH2-N), 
6.80 (t, 1H, Ar-H), 6.94 (d, 2H, Ar-H), 7.16-7.28 (m, 9H, Ar-H), 
7.51  (d, 1H, Ar-H), 7.65 (d,1H, Ar-H) EIMS(m/z): 382(M+). 
Elemental analysis: (found/calculated) C, 78.43/78.50; H, 
6.87/6.85; N, 14.70/14.65 
Anti-inflammatory Activity   
The anti-inflammatory activity of the target compounds (42-
a to 42-j) were tested by carrageenan induced inflammation 
in rat paw edema. 
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Table 3: Anti-inflammatory activity of the piperazine derivatives (42-a to 42-j) 
Treatment 
Dose 
(mg/kg) 
Carrageenan induced paw edema 
Increase in paw 
edema 
(mm) 
% inhibition 
Increase in paw 
edema 
(mm) 
% inhibition 
 
After 1 hour After 3 hour 
1 control 1.40±0.17 - 1.98±0.14 - 
2 (Aspirin) 50 0.92±0.18 34.28 0.52±0.16 73.73 
42-a 50 1.10±0.15 21.42 1.38±0.17 30.30 
42-b 50 1.20±0.15 14.28 1.49±0.18 24.74 
42-c 50 1.03±0.16 26.42 1.13±0.13 42.92 
42-d 50 1.08±0.13 22.85 1.22±0.17 38.38 
42-e 50 1.15±0.11 17.86 1.41±0.16 28.78 
42-f 50 1.13±0.18 19.28 1.34±0.17 32.32 
42-g 50 1.18±0.14 15.71 1.37±0.15 30.80 
42-h 50 1.01±0.16 27.85 1.15±0.13 41.91 
42-i 50 1.07±0.15 23.57 1.28±0.15 35.35 
42-j 50 1.18±0.11 15.71 1.45±0.14 26.26 
Number of Animals used n = 3 
Dose of the test compounds and standard drug = 50 mg/kg 
 
 
Figure 2: Column chart showing % inhibition 
 
DISCUSSION 
Compounds (42-a to 42-j) were screened for anti-
inflammatory activity by inhibition of carrageenan induced 
rat paw edema method at the dose of 10 mg/kg. Significant 
anti-inflammatory activity was observed with inhibition in 
the range of after 3 h. Aspirin showed 73.73% inhibition 
after 3 h. Among all the screened compounds, 42-c & 42-
hwere found to be the most potent in the series with 
inhibition after 3 h. Among all the screened compounds, 42-b 
& 42-j were found least potent in the series with respect to 
standard after 3 h. 
CONCLUSION 
In conclusion, we reported here a series of 1,4-disubstituted 
piperazine derivatives as anti-inflammatory agents. 
Synthesized compounds (42-c, 42-d &42-h) exhibit good 
anti-inflammatory activity but two of them (42-b and 42-i) 
are less potent, while another five (42-a, 42-e, 42-f, 42-g and 
42-j) have significant activity. Compound (42-c) was most 
potent among the series of synthesized compounds as anti-
inflammatory agents. 
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